1010729-04-0

Basic information

• Product Name: (S)-N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide
• Synonyms: (S)-N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide
• CAS NO: 1010729-04-0
• Molecular Weight: 236.658
• Mol File: 1010729-04-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide(1010729-04-0)
• EPA Substance Registry System: (S)-N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide(1010729-04-0)

Safety Data

• Hazardous Substances Data: 1010729-04-0(Hazardous Substances Data)

Upstream product

• 20925-27-3 4-amino-2-chlorobenzonitrile 
• 1002330-78-0 (2R)-3-bromo-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-methylpropanamide 

Downstream Products

• 928122-40-1 ((S)-N-(3-chloro-4-cyanophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide) 

Relevant articles and documents

Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer

A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different ba

New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity

In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.

SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.